share_log

Decoding The Spike: Understanding Aditxt (ADTX) Shares' Significant Increase

Decoding The Spike: Understanding Aditxt (ADTX) Shares' Significant Increase

解讀峯值:了解Aditxt(ADTX)股票的大幅上漲
Stocks Telegraph ·  04/03 00:05

Aditxt, Inc. (NASDAQ: ADTX) is observing a notable surge of 25.47% in its shares during the current session, escalating to a price of $3.99. This significant increase in ADTX shares within the US market can be directly attributed to the disclosure of an acquisition agreement.

Aditxt, Inc.(納斯達克股票代碼:ADTX)在本交易日觀察到其股價顯著上漲25.47%,漲至3.99美元。美國市場上ADTX股票的大幅增長可以直接歸因於收購協議的披露。

Aditxt (ADTX) officially stated today that it has reached a formal arrangement agreement to acquire Appili Therapeutics Inc. is a biopharmaceutical company that emphasis on developing drugs for infectious illnesses and medical countermeasures.

Aditxt(ADTX)今天正式表示,它已達成收購Appili Therapeutics Inc.的正式安排協議。Appili Therapeutics Inc.是一家專注於開發傳染病和醫療對策藥物的生物製藥公司。

Adivir, Inc., Aditxt's wholly owned subsidiary, has agreed to purchase all of Appili's issued and outstanding Class A common shares under a court-approved plan of arrangement under the Canada Business Corporations Act.

Aditxt的全資子公司Adivir, Inc. 已同意根據法院批准的《加拿大商業公司法》安排計劃購買Appili所有已發行和流通的A類普通股。

The FDA-approved LIKMEZ (formerly ATI-1501), the ATI-1701 biodefense program supported by a USD $14 million non-dilutive award from the US Department of Defense, and ATI-1801, a topical formulation aimed at cutaneous leishmaniasis—a crippling disease that causes pain and disfigurement—are just a few of the varied portfolio items that Appili has developed since its establishment in 2015.

美國食品藥品管理局批准的LIKMEZ(前身爲 ATI-1501)、由美國國防部1,400萬美元非稀釋獎勵支持的 ATI-1701 生物防禦計劃,以及針對皮膚利什曼病(一種導致疼痛和毀容的嚴重疾病)的局部配方 ATI-1801 只是Appili自2015年成立以來開發的各種投資組合項目中的一小部分。

This acquisition will enrich Aditxt's array of subsidiaries and foster synergies with its existing initiatives, notably in precision diagnostics. The amalgamation of Appili's proficiency and product lines will facilitate a holistic approach to public health, encompassing early detection, prevention, and treatment. Collaborative opportunities within the Aditxt ecosystem promise to streamline patient care, from early detection through precise diagnostics to tailored treatment strategies.

此次收購將豐富Aditxt的子公司範圍,並促進與其現有舉措的協同效應,特別是在精密診斷方面。Appili的能力和產品線的整合將促進採取全面的公共衛生方法,包括早期發現、預防和治療。Aditxt 生態系統內的合作機會有望簡化患者護理,從早期發現到精確診斷再到量身定製的治療策略。

The incorporation of Appili into Aditxt's framework signifies another stride in advancing promising health innovations. With the integration of Appili's proven track record and broad portfolio in biodefense and infectious illnesses, Aditxt is well-positioned to have a substantial impact on the development of public health solutions.

將Appili納入Aditxt的框架標誌着在推進有前景的健康創新方面又取得了長足的進步。通過整合Appili在生物防禦和傳染病領域的良好記錄和廣泛的產品組合,Aditxt完全有能力對公共衛生解決方案的開發產生重大影響。

Under the Canada Business Corporations Act, the Transaction will take place through a plan of arrangement that has been approved by the court. Adivir will purchase all issued and outstanding Appili Shares in accordance with the provisions of the Arrangement Agreement, and each Appili Shareholder will receive US$0.0467 for each Appili Share held in addition to 0.002745004 of a share of Aditxt's common stock.

根據《加拿大商業公司法》,交易將通過法院批准的安排計劃進行。Adivir將根據安排協議的規定購買所有已發行和流通的Appili股票,除了Aditxt普通股的0.002745004股外,每位Appili股東每持有的Appili股票將獲得0.0467美元。

The Transaction is contingent upon the approval of at least two-thirds of the votes cast at the special meeting of the Appili Shareholders, projected to convene before the conclusion of calendar Q2 2024 for approval of the Transaction.

該交易取決於Appili股東特別會議上至少三分之二的選票的批准,該特別會議預計將在日曆2024年第二季度結束之前召開,以批准該交易。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論